Drug intelligence / Profile preview

CA-051

Development stage: Preclinical
Lead developer: Concentric Analgesics
Modality: Small Molecules
Administration: Epidural

Overview

CA-051 is a small molecule drug candidate developed by Concentric Analgesics. It acts as an agonist of the TRPV1 (transient receptor potential vanilloid 1) channel, also known as the vanilloid receptor. The drug is being investigated primarily for its analgesic properties, with a focus on treating cancer pain and postoperative pain. Its mechanism involves activation of TRPV1, which plays a role in pain signaling pathways within the nervous system. As of March 2025, CA-051 remains in preclinical development and has not yet reached clinical trial phases or received regulatory approval[1][6].

Targets

TRPV1 (Transient receptor potential cation channel subfamily V member 1)

Beyond the preview

Go deeper on CA-051.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CA-051.

Explore the full profile